Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 430 participants.

Also called NCT07244003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 430 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07244003
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07244003. Randomized; no masking; primary purpose treatment. Start 2025-03-29 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control
Acronym
MESSAGE
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
Metformin
Intervention (Drug)
Triple Therapy of Other Oral Antidiabetic Drugs
Intervention (Drug)
ganagliflozin
Intervention (Drug)
liraglutide
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07244003
Content hash
94ad0c3eefed3a6a9ef6531d35b3367aec30bd600378edabb95b0d860561eece